Clinical trial
A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)
NCT05709314 is registered in ClinicalTrials.gov with Amydis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)
- Lead sponsor
- Amydis Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 9, 2024
- Completion date
- December 31, 2026
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.